Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

All content curated by

Silvio Inzucchi MD

Richard Pratley MD

Deborah Wexler MD, MSc

See All Experts

story of the week

Published in Diabetes and

Journal Scan / Research · August 01, 2024

GLP-1 Receptor Agonists and SGLT2 Inhibitors for Treatment of Diabetes in Liver Transplant Recipients

Diabetes, Obesity & Metabolism

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Carolina Gonzalez-Lopez MD

Diabetes, Obesity & Metabolism

Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients

Diabetes Obes Metab 2024 Jul 26;[EPub Ahead of Print], K Zheng, A Azhie, X You, M Naghibzadeh, E Tan, S Naimimohasses, VS Sridhar, S Gupta, S Chen, S Dash, C Tsien, N Selzner, L Lilly, E Jaeckel, M Woo, S Singh, D Cherney, M Bhat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Obesity, Metabolic Syndrome, and Prediabetes

GLP-1 Receptor Agonists and SGLT2 Inhibitors for Treatment of Diabetes in Liver Transplant Recipients

Additional Info

Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients

Further Reading

Association Between Iron Status and Insulin Resistance in Adults From the US

Association Between Mean Platelet Volume and the Risk of Type 2 Diabetes in Women With a History of Gestational Diabetes Mellitus

Deviations in HbA1c in Relation to Mean Glucose Levels and Time in Range Among Individuals With Type 1 Diabetes

Liver Fat Accumulation Is Associated With Increased Insulin Secretion Independent of Total, Visceral, and Pancreatic Fat

Clinical Effectiveness of Continuous Glucose Monitoring in Pregnancies Affected by Type 1 Diabetes

Heterogeneity of Glycaemic Phenotypes in Type 1 Diabetes

Identification and Validation of Gestational Diabetes Subgroups by Data-Driven Cluster Analysis

Use of Semaglutide for the Primary Prevention of Diabetic Kidney Disease in People With Type 2 Diabetes

Associations Between Hypoglycemia Awareness Status and Symptoms of Hypoglycemia in Adults With Type 1 or Insulin-Treated Type 2 Diabetes Using Hypo-METRICS App

Accuracy of Continuous Glucose Monitoring in the Hospital Setting

Comparison of Renal Prognosis Between DPP-4 Inhibitor Users and Non-Users

Recently Updated